W
Walter J. Storkus
Researcher at University of Pittsburgh
Publications - 285
Citations - 19025
Walter J. Storkus is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Immune system & Cytotoxic T cell. The author has an hindex of 67, co-authored 270 publications receiving 18010 citations. Previous affiliations of Walter J. Storkus include Duke University & University of Regensburg.
Papers
More filters
Journal ArticleDOI
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
Jose I. Mayordomo,Tatiana D. Zorina,Walter J. Storkus,Laurence Zitvogel,Christina M. Celluzzi,Louis D. Falo,Cornelis J. M. Melief,S. T. Ildstad,Wybe Martin Kast,Albert B. DeLeo +9 more
TL;DR: Treatment of animals bearing established macroscopic tumours with tumour peptide-pulsed dendritic cells resulted in sustained tumour regression and tumour-free status in more than 80% of cases, and support the clinical use of tumour Peptide-Pulsed Dendritic Cells as components in developing effective cancer vaccines and therapies.
Journal ArticleDOI
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Laurence Zitvogel,Jose I. Mayordomo,Tjendimin Tjandrawan,Albert B. DeLeo,Martha R. Clarke,Michael T. Lotze,Walter J. Storkus +6 more
TL;DR: Using the immunogenic C3 (H-2b) tumor model in B6 mice, tumor peptide-pulsed DC therapy resulted in the erradication of established d14 tumors and long-term survival in 100% of treated animals.
Journal Article
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
C. L. Nastala,H. D. Edington,T. G. McKinney,Hideaki Tahara,Michael A. Nalesnik,Michael J. Brunda,Maurice K. Gately,Stanley F. Wolf,Robert D. Schreiber,Walter J. Storkus +9 more
TL;DR: IL-12 is an effective and minimally toxic antitumor agent in murine tumor models and leads to an immune-mediated rejection involving, at least in part, IFN-gamma, CD4+, and CD8+ cells.
Journal ArticleDOI
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
TL;DR: It is shown that major histocompatibility complex class I- presented peptide antigen pulsed onto dendritic APCs induces protective immunity to lethal challenge by a tumor transfected with the antigen gene.
Journal ArticleDOI
α-Type-1 Polarized Dendritic Cells A Novel Immunization Tool with Optimized CTL-inducing Activity
Robbie B. Mailliard,Anna Wankowicz-Kalinska,Quan Cai,Amy Wesa,Catharien M. U. Hilkens,Martien L. Kapsenberg,John M. Kirkwood,Walter J. Storkus,Pawel Kalinski +8 more
TL;DR: Serum-free generation of alphaDC1 allows, for the first time, the clinical application of DCs that combine the key three features important for their efficacy as anticancer vaccines.